

## EUCAST Steering Committee Meeting Summary Barcelona, Spain, 22-23 April 2008

### Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Prof Waleria Hryniewicz	WH	EUCAST	Poland
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Inga Odenholt	IO	SRGA	Sweden
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	CS	CA-SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway

### Apologies

Prof Pietro Varaldo	PV	EUCAST	Italy
---------------------	----	--------	-------

### EMA (23 April)

Dr Eric Pelfrene	MB	EMA, London
Dr Mair Powell	MP	MHRA, London
Dr Norbert Schnitzler	NS	Bonn, Germany

1	<b>Chairman's welcome</b>
2	<b>Minutes of meeting of 28-29 January 2008</b> Accepted as a correct record.
3	<p><b>Matters arising from minutes of 28-29 January 2008</b></p> <p>Minocycline MIC data is yet to be provided.</p> <p>Quinupristin-dalfopristin data is to be requested.</p> <p>Data relating to moxifloxacin for anaerobic intra-abdominal infections should be available soon.</p> <p>Anaerobe MIC distributions are to be added to the wild type MIC distributions website.</p> <p>Responses in relation to questions on a new glycopeptide have been received.</p> <p>Proposals regarding revised breakpoints for a new carbapenem have been sent to the company.</p> <p>A revised table on status of technical notes and rationale documents has been prepared.</p> <p>Minutes related to meetings with companies on a new diaminopyrimidine and a new glycopeptide were sent to the companies.</p> <p>Harmonised breakpoints for miscellaneous agent are close to completion.</p> <p>Tetracycline breakpoints for <i>N. gonorrhoeae</i> were discussed.</p> <p>Harmonised breakpoints for tetracyclines are close to completion.</p> <p>A footnote regarding <i>Shigella</i> and azithromycin has been added to the macrolide breakpoint table.</p> <p>Comments on proposed penicillin breakpoints were distributed with the latest version of the table.</p> <p>Noted that proposed anaerobe breakpoints for penicillins were based on MIC distributions.</p> <p><i>P. mirabilis</i> has been added to footnote 5 of the cephalosporin breakpoint table.</p>

4	<b>New drugs</b> The status of new agents was reviewed.
5	<b>EUCAST documents</b> The status of EUCAST documents was reviewed.
6	<b>Expert rules subcommittee</b> Version 1.0 of the document is on the EUCAST website. Possible future developments were discussed including publication as a supplement in CMI and development of a stand-alone program for application of the expert rules. If presenters agree, presentations from the ECCMID workshop will be posted in pdf format on the EUCAST website.
7	<b>Antifungal susceptibility testing subcommittee</b> Publication of a new document on susceptibility testing of filamentous fungi was discussed. A CEN/ISO method for antifungal agents is being developed.
8	<b>Anaerobe subcommittee</b> A proposal will be made to ECCMID to work on a microdilution method for anaerobes as agar dilution is currently recommended. Separate breakpoints have been proposed for Gram-positive and Gram-negative anaerobes.
9	<b>Penicillin breakpoints</b> The draft breakpoint table was reviewed and will be updated to what is expected to be the final version.
10	<b>Financing of EUCAST</b> ECDC will issue a new call for a susceptibility testing project. A separate call for development of a disk diffusion method is expected later this year.
11	<b>Review of EUCAST breakpoints</b> Breakpoint that require review were discussed and glycopeptides and staphylococci, ciprofloxacin and <i>Pseudomonas</i> , and carbapenems and Enterobacteriaceae/ <i>Pseudomonas</i> were highlighted as priorities.
12	<b>CLSI</b> No new information.
13	<b>ECCMID</b> Noted that responses to the 2008 workshop and symposium were very positive and attendance was very good. Proposals for 2009 will be sent to ECCMID.
14	<b>Disk diffusion questionnaire</b> Replies had been received from almost all countries, with more than one reply from some. Almost all agree that a EUCAST disk diffusion method is needed and should be based on 0.5 MacFarland inoculum and MH agar.
15	<b>ECDC</b> National Antimicrobial Committees will be promoted for consultation, development of strategy and implementation of European decisions on all aspects of antimicrobials.
16	<b>New glycopeptide</b> Proposed breakpoints were discussed further.
17	<b>EMEA</b> The current status of new agents was presented.
18	<b>Oral cephalosporins</b> A draft table of breakpoints was reviewed.
19, 20	<b>New quinolone</b> The status was reviewed before a meeting with the company.
21	<b>Any other business</b> Prof Waleria Hryniewicz and Prof Pietro Varaldo have completed their terms as representatives of the EUCAST General Committee and were thanked for their contributions.
22	<b>Next meetings</b> 12-13 June 2008. Birmingham, UK 8-9 September 2008. Växjö, Sweden 24-25 November 2008. Rome, Italy 26-27 January 2009. 19-20 May 2009. Helsinki, Finland (following ECCMID)

Ratified summary of minutes of meeting 22-23 April 2008. Prepared by DB, GK and RC